Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NG9 | ISIN: US83548R4020 | Ticker-Symbol: H3D0
NASDAQ
03.07.25 | 18:41
4,070 US-Dollar
-1,93 % -0,080
1-Jahres-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
SONNET BIOTHERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur SONNET BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSonnet BioTherapeutics schließt Verkauf von Wandelanleihen und Optionsscheinen im Wert von 2 Millionen US-Dollar ab22
MiSonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report3
SONNET BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
02.06.Sonnet Biotherapeutics erhält Delisting-Mitteilung von der NASDAQ13
02.06.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
13.05.Sonnet BioTherapeutics Holdings, Inc. - 10-Q, Quarterly Report4
01.05.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit2
16.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Releases Virtual Investor "What This Means" Segment4
04.04.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report5
04.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest ...262Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination...
► Artikel lesen
01.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Announces Release of Corporate Update Video3
01.04.Sonnet BioTherapeutics ernennt Interims-CEO nach dem Tod des Gründers2
01.04.Sonnet BioTherapeutics appoints interim CEO after founder's death3
01.04.Sonnet BioTherapeutics Holdings, Inc.: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.187PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted...
► Artikel lesen
26.03.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas213SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy...
► Artikel lesen
26.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report2
19.03.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report3
19.03.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant ...203Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable...
► Artikel lesen
26.02.Sonnet BioTherapeutics Holdings, Inc.: Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors4
26.02.Sonnet BioTherapeutics Holdings, Inc. - 8-K, Current Report1
19.02.Sonnet BioTherapeutics advances novel ADC platform1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1